Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients

According to a British study, Eli Lilly And Co LLY and Incyte Corporation's INCY Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%.
According to a Reuters report, more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial.
Results showed that 546 patients in the standard of care group died within 28 days, compared to 513 patients in the baricitinib group who died where they were also given a corticosteroid like dexamethasone, tocilizumab, or remdesivir.
Related: WHO Recommends Glaxo, Eli Lilly Drugs For COVID-19 Treatment Amid Omicron Surge.
"This result confirms and extends earlier findings, providing greater certainty that baricitinib is beneficial and new data to guide the treatment of COVID-19 patients with a combination of drugs to dampen the immune response," said Peter Horby, Oxford professor and joint chief investigator.
In the RECOVERY trial, baricitinib also increased the chances of patients being discharged alive within 28 days and reduced the risk of their condition worsening, scientists said.
Price Action: LLY shares are up 0.93% at $256.54, INCY shares are down 1.16% at $68.78 during the market session on the last check Thursday.